Demonstrate the safety and efficacy of ventilation with Ventrain® during 5 minutes. Safety is demonstrated if the peak pressure during insufflation does not exceed 25 cm H2O and PEEP (Positive End Expiratory Pressure) is not smaller than -5 cm H2O…
ID
Source
Brief title
Condition
- Upper respiratory tract disorders (excl infections)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Demonstrate the safety and efficacy of ventilation with Ventrain® during 5
minutes. Safety is demonstrated if the peak pressure during insufflation does
not exceed 25 mm H2O and PEEP is not smaller than -5 mm H2O and not higher than
6 mm H2O. The number of interventions from the safety-person dr. C will be the
primary endpoint. We assume that the interventionrate will be less than 15%.
Powercalculation
As this can be seen as a pilot study and no information is available at this
moment.
However. the primary outcome is the number of interventions from the
safety-person dr. C . We assume that this will be less than 15%. With 20
patients we can exclude the possibility that this failure proportion is higher
than 13.9%. One sided tested the CI will be less than 13.9%.
Secondary outcome
Measure the different parameters during ventilation with the Ventrain® as there
are lung pressure, peak lung pressure, PEEP, capno, oxygen saturation, tension
and heart rhythm.
Background summary
Ventrain® is the first ventilation device that provides adequate ventilation
through a narrow-bore catheter, even in case of a completely obstructed upper
airway. Ventrain®, a product specifically designed for *cannot intubate, cannot
ventilate* emergencies, makes airway management in such life-threatening
situations easier and safer. With Ventrain, we have full ventilation through
only a 2 mm catheter.
Ventrain® not only insufflates oxygen, but also provides active removal of
gas from the lungs: expiratory ventilation assistance, or in short EVA.
EVA shortens the expiration time, increases the achievable minute volume and
prevents air trapping. Therefore, Ventrain® considerably reduces the chance
of intrapulmonary pressure build-up and the associated risks of barotrauma
and circulatory collapse. Active expiration is created by the special design
that optimizes a
balance between the Venturi effect and jet entrainment.
Ventrain® has been used in several cases of emergency of which several cases
have been published (ref). It has even been used in two life-saving airway
emergencies in neonates (ref).
These publications have been single cases. Despite several tests in animals and
lung simulators, there are still some worries for high pressures during
ventilation. In the present study we would like to demonstrate the safety of
ventilation (during 5 minutes) with Ventrain® in a series of patients prepared
for an operation. During reanimations generally no pressure or other
measurements are performed. During these controlled and well planned
ventilations these measurements can be performed.
Study objective
Demonstrate the safety and efficacy of ventilation with Ventrain® during 5
minutes. Safety is demonstrated if the peak pressure during insufflation does
not exceed 25 cm H2O and PEEP (Positive End Expiratory Pressure) is not smaller
than -5 cm H2O and not higher than 6 cm H2O.
Study design
1. Patients are approached to participate in the study during the pre-operative
period by the anaesthesist.
2. Patients will have at least 1 week to think about the study and will then be
approached for their answer.
3. Patients willing to be included will be planned for an OR at a time that the
study can be performed.
4. For the OR an additional +- 15 minutes will be scheduled.
5. All patients will be intubated as usual with a tube of 7-8 mm. The tube is
prepared on the OR with an airway exchange catheter Cook 3 mm and with a line
for pressure measurements. The insertion of these materials will be facilitated
by wetting the materials with sterile water.
6. The prepared tube will be brought into the patient.
7. From the moment that the ventilation of the patient starts two persons will
be available for the ventilation. The first person (named dr B, as he will be
blind for the pressure measurements) will perform the ventilation with the
Ventrain. Dr B will only look at the patient and its chest.
8. The second person (dr C will control the pressures and makes sure that the
patient never gets the boundaries of the pressures as stated earlier in the
protocol. Dr C has the right and is obliged to finish the experiment at the
moment the pressure boundaries are reached.
9. Dr B will use the Ventrain® as stated in the instructions for use, which
means that after 5 ventilation cycles the Ventrain® is opened until the chest
is in rest.
10 As a small tidal volume is preferred, the ratio of inspiration and
expiration will be 1:1, which means 1 second inspiration and 1 second
expiration.
11. The flow of the 100% oxygen will be set at 15 L/min.
12. The ventilation will be performed with the Ventrain® during 5 minutes.
13. After 5 minutes the Cook catheter and line for pressure measurements will
be withdrawn from the tube. The 7-8 mm tube stays in situ during the following
OR period.
14. The ventilation of the patient will be continued as normal.
15. Several measurement will be continued during the first 5 minutes of
ventilation, such as oxygen saturation, heart rhythm and tension.
16. The OR will continue as usual. The experiment has ended.
Study burden and risks
The risk can be compared with the risk around normal operation procedures and
each ventilation procedure.
The safety is guaranteed as a second person is taking care for the monitors and
he/she will intervene if necessary.
The burden for the patient will be limited to a prolonged narcosis of maximal
15 minutes. We assume it will be around 5 minutes.
dr. H van het Hoffplein 1
Sittard 6130MB
NL
dr. H van het Hoffplein 1
Sittard 6130MB
NL
Listed location countries
Age
Inclusion criteria
- ASA 1-2
- Planned for operation from orthopaedic, gynaecology or ENT
- Aged above 18 years and under 65
Exclusion criteria
- ASA more than 2
- Aged under 18
- Aged above 65
- Respiratory disease
- Cardiovascular disease
- Smokers
- Obese patients
- Pregnancy
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL50090.096.14 |